Innovent Biologics (HKG:1801) recorded a product revenue of over 2.7 billion yuan in the second quarter, up 30% from a year prior, a Thursday Hong Kong bourse filing said.
In the first half of 2025, the drug company's product revenue rose 35% year over year to over 5.2 billion yuan.
The higher revenue was driven by the oncology and general biomedicine product portfolios.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.